Using the agreed starting and stopping criteria, vonicog alfa (Veyvondi^®▼) can be made available within NHS Wales for on-demand treatment of non-surgical and surgical (elective and emergency) bleeding episodes in children aged up to 17 years with von Willebrand disease. Vonicog alfa (Veyvondi^®▼) will be available as a second line treatment, given when desmopressin treatment with or without tranexamic acid is ineffective or not indicated.

The risks and benefits of the off-label use of vonicog alfa (Veyvondi^®▼) for this indication should be clearly stated and discussed with the patient to allow informed consent.

Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.

In November 2022 OWMAG recommended this treatment in NHS Wales, in November 2023 there was a review of the recommendation. OWMAG found nothing new that affects the original decision.

Next review: this decision will be reviewed again after 12 months or earlier if new evidence becomes available.